Medtronic (NYSE:MDT) put a total of $316 million on the table to acquire Epix Therapeutics, including a $100 million earn-out. The Fridley, Minn.-based company, which is the world’s largest pure-play medical device maker, in January announced the deal for Epix, formerly known as Advanced Cardiac Therapeutics, without revealing further terms. In a regulatory filing last week, […]
Medtronic (NYSE:MDT) said yesterday that it inked a deal to acquire cardiac ablation tech developer Epix Therapeutics, formerly known as Advanced Cardiac Therapeutics, for an undisclosed amount. Santa Clara, Calif.-based Epix’s flagship device is the DiamondTemp catheter-based radiofrequency cardiac ablation system, which won CE Mark approval in the European Union in 2017. The company is engaged […]
Perhaps there’s a ray of hope that venture capital funding is recovering a bit for the medical device industry. VC firms invested more than $2.8 billion in 2017, an increase of more than $647 million from 2016, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There were a total 229 deals involving […]
Advanced Cardiac Therapeutics said yesterday the 1st 12 patients have been treated using its open-irrigated radio frequency ablation technology to treat atrial fibrillation. The treatments were performed in Prague by study principal investigator Dr. Vivek Reddy of Mt. Sinai Hospital, the company said. ACT’s RF tech incorporates a generator with a novel temperature-sensing low-flow catheter […]
October 30, 2014 by Val Kennedy
The FDA announced today that it cleared the Siemens AG (NYSE:SI) Biograph, the first device to perform positron emission tomography scanning and magnetic resonance imaging scanning at the same time.
PET scans allow physicians to see how organs are functioning by injecting radioactive tracers into a patient’s blood stream and MRIs use magnetic fields and radiowaves to create detailed images of organs, soft tissues, bones and other body structures.
Svelte Medical Systems Inc. closed a six-month follow-up analysis for the first clinical trial of its Acrobat angioplasty system.
CEO Mark Pomeranz said the "excellent" results from the Europe and South America-based trial are a "significant milestone" for the New Providence, N.J.-based company.
The company calls the Acrobat device an "all in one" stenting system.